Author

M. Sokolsky-Papkov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Research Focus:benchmarking· 1 Research Focus:host-pathogen & immune response· 1 Organism:non-human primate· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

C. Lim· 3 shared D. Hwang· 3 shared A. V. Kabanov· 2 shared J. D. Ramsey· 2 shared N. Vinod· 2 shared A. E. D. Van Swearingen· 1 shared A. Kabanov· 1 shared B. W. Day· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Lim

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cancer BiologybioRxivAug 12, 2022

High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer

C. Lim, D. Hwang, M. Yazdimamaghani…·A. Kabanov

This study evaluates high-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple-negative breast cancer, showing improved therapeutic outcomes and immune response.

DOI 10.1016/j.nantod.2023.101884

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 14, 2022

Targeting OLIG2 increases therapeutic responses in SHH medulloblastoma mouse models and patient-derived medulloblastoma organoids

Y. Li, T. Dismuke, C. Lim…·B. W. Day

This study shows that targeting OLIG2 with CT-179 reduces recurrence in SHH medulloblastoma models and improves survival when combined with radiotherapy.

DOI 10.1101/2022.02.14.480293

mouseorganoid / primary culture

𝕏 PostBluesky

Pharmacology & ToxicologyBiomaterialsPeer-reviewedNov 1, 2021

Bioequivalence Assessment of High-Capacity Polymeric Micelle Nanoformulation of Paclitaxel and Abraxane(R) in Rodent and Non-Human Primate Models Using a Stable Isotope Tracer Assay

D. Hwang, N. Vinod, S. L. Skoczen…·A. V. Kabanov

DOI 10.1016/j.biomaterials.2021.121140

ratnon-human primate

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivDec 12, 2019

High Capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of Lung Adenocarcinoma

N. Vinod, D. Hwang, S. H. Azam…·A. V. Kabanov

This study shows that a novel nanomicellar formulation of Resiquimod extends survival in a metastatic lung adenocarcinoma model more effectively than chemotherapy and anti-PD1 therapy.

DOI 10.1126/sciadv.aba5542

mouseexperimental assay

𝕏 PostBluesky